KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Other financing activities (2017 - 2019)

Neogenomics filings provide 5 years of Other financing activities readings, the most recent being $8000.0 for Q4 2019.

  • On a quarterly basis, Other financing activities changed N/A to $8000.0 in Q4 2019 year-over-year; TTM through Dec 2020 was $105000.0, a 0.0% change, with the full-year FY2019 number at $1.1 million, up 83.85% from a year prior.
  • Other financing activities hit $8000.0 in Q4 2019 for Neogenomics, down from $97000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $576000.0 in Q2 2018 to a low of -$112000.0 in Q3 2017.
  • Median Other financing activities over the past 4 years was $97000.0 (2016), compared with a mean of $129666.7.
  • The widest YoY moves for Other financing activities: up 15.46% in 2017, down 15.46% in 2017.
  • Neogenomics' Other financing activities stood at $97000.0 in 2016, then crashed by 215.46% to -$112000.0 in 2017, then soared by 614.29% to $576000.0 in 2018, then crashed by 98.61% to $8000.0 in 2019.
  • The last three reported values for Other financing activities were $8000.0 (Q4 2019), $97000.0 (Q3 2019), and $576000.0 (Q2 2018) per Business Quant data.